Date: 2014-10-01
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, in Barcelona, Spain, on November 18-21, 2014.
Company: Genoscience Pharma (France)
Product: GNS561
Action mechanism:
Disease: hepatocellular carcinoma
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On October 1, 2014, Genoscience Pharma, a company focused on discovering and developing small molecules to treat cancer by targeting cancer stem cells, announced that it will present data on its most promising candidate at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, in Barcelona, Spain, on November 18-21, 2014. Two lead compounds have been selected: GNS396 to treat acute myeloid leukemia (AML) and GNS561 to treat hepatocellular carcinoma.
